Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Weight Loss | 24 | 2024 | 480 | 7.430 |
Why?
|
| Obesity | 28 | 2024 | 1175 | 5.550 |
Why?
|
| Caloric Restriction | 11 | 2024 | 106 | 4.060 |
Why?
|
| Body Composition | 15 | 2019 | 397 | 3.340 |
Why?
|
| Exercise | 12 | 2023 | 672 | 2.800 |
Why?
|
| Bone Density | 9 | 2024 | 205 | 2.680 |
Why?
|
| Diet, Reducing | 8 | 2020 | 106 | 2.640 |
Why?
|
| Inflammation | 10 | 2013 | 530 | 2.420 |
Why?
|
| Overweight | 8 | 2016 | 280 | 1.980 |
Why?
|
| Dietary Proteins | 4 | 2019 | 55 | 1.850 |
Why?
|
| Bone Density Conservation Agents | 2 | 2024 | 23 | 1.740 |
Why?
|
| Aged | 41 | 2024 | 10301 | 1.650 |
Why?
|
| Resistance Training | 3 | 2024 | 82 | 1.590 |
Why?
|
| Physical Fitness | 4 | 2013 | 131 | 1.530 |
Why?
|
| Aging | 9 | 2017 | 946 | 1.450 |
Why?
|
| Adipose Tissue | 4 | 2020 | 349 | 1.360 |
Why?
|
| Female | 49 | 2024 | 19959 | 1.330 |
Why?
|
| Bone and Bones | 3 | 2023 | 94 | 1.280 |
Why?
|
| Adiposity | 4 | 2020 | 198 | 1.220 |
Why?
|
| Interleukin-6 | 6 | 2023 | 247 | 1.180 |
Why?
|
| Humans | 56 | 2024 | 32005 | 1.160 |
Why?
|
| Male | 39 | 2024 | 19165 | 1.160 |
Why?
|
| Body Mass Index | 12 | 2023 | 923 | 1.150 |
Why?
|
| Weight Gain | 4 | 2017 | 117 | 1.110 |
Why?
|
| Gait | 2 | 2020 | 142 | 1.070 |
Why?
|
| Soy Milk | 3 | 2010 | 3 | 1.070 |
Why?
|
| Postmenopause | 7 | 2017 | 430 | 1.060 |
Why?
|
| Fractures, Bone | 4 | 2020 | 148 | 1.000 |
Why?
|
| Soybean Proteins | 4 | 2015 | 74 | 0.970 |
Why?
|
| Alendronate | 1 | 2024 | 11 | 0.970 |
Why?
|
| Cardiovascular Diseases | 6 | 2019 | 1128 | 0.950 |
Why?
|
| Middle Aged | 28 | 2024 | 11817 | 0.930 |
Why?
|
| Motor Activity | 4 | 2014 | 325 | 0.930 |
Why?
|
| Obesity, Morbid | 3 | 2020 | 73 | 0.920 |
Why?
|
| Gastrectomy | 2 | 2021 | 68 | 0.910 |
Why?
|
| Absorptiometry, Photon | 6 | 2024 | 143 | 0.860 |
Why?
|
| Muscle, Skeletal | 6 | 2023 | 519 | 0.810 |
Why?
|
| Milk | 3 | 2010 | 16 | 0.810 |
Why?
|
| Inflammation Mediators | 3 | 2012 | 104 | 0.760 |
Why?
|
| Uric Acid | 2 | 2013 | 27 | 0.750 |
Why?
|
| Mortality | 2 | 2019 | 125 | 0.740 |
Why?
|
| Bariatric Surgery | 1 | 2020 | 26 | 0.720 |
Why?
|
| Continental Population Groups | 1 | 2020 | 237 | 0.640 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2016 | 1428 | 0.630 |
Why?
|
| Oxidative Stress | 2 | 2010 | 231 | 0.620 |
Why?
|
| Abdominal Fat | 2 | 2015 | 50 | 0.580 |
Why?
|
| Walking | 5 | 2020 | 209 | 0.570 |
Why?
|
| Endometrial Neoplasms | 1 | 2017 | 49 | 0.550 |
Why?
|
| Cognition | 2 | 2016 | 555 | 0.500 |
Why?
|
| Life Style | 3 | 2014 | 408 | 0.500 |
Why?
|
| Muscle Strength | 2 | 2018 | 161 | 0.490 |
Why?
|
| Isoflavones | 3 | 2010 | 81 | 0.490 |
Why?
|
| Blood Pressure | 3 | 2015 | 845 | 0.460 |
Why?
|
| Cytokines | 3 | 2011 | 256 | 0.460 |
Why?
|
| Adiponectin | 2 | 2013 | 106 | 0.460 |
Why?
|
| Prediabetic State | 1 | 2014 | 65 | 0.460 |
Why?
|
| Kidney Failure, Chronic | 2 | 2009 | 543 | 0.460 |
Why?
|
| Diet | 3 | 2011 | 391 | 0.450 |
Why?
|
| Pilot Projects | 4 | 2021 | 545 | 0.430 |
Why?
|
| Soy Foods | 2 | 2010 | 7 | 0.430 |
Why?
|
| Cause of Death | 1 | 2013 | 236 | 0.420 |
Why?
|
| Single-Blind Method | 6 | 2015 | 203 | 0.420 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2020 | 510 | 0.420 |
Why?
|
| Nonprescription Drugs | 2 | 2009 | 23 | 0.420 |
Why?
|
| Follow-Up Studies | 8 | 2017 | 2265 | 0.410 |
Why?
|
| Insulin Resistance | 2 | 2014 | 462 | 0.410 |
Why?
|
| Coronary Disease | 1 | 2013 | 211 | 0.410 |
Why?
|
| Corn Oil | 2 | 2009 | 3 | 0.400 |
Why?
|
| Age Factors | 5 | 2020 | 1188 | 0.390 |
Why?
|
| Risk Factors | 8 | 2017 | 3876 | 0.380 |
Why?
|
| Tumor Necrosis Factors | 1 | 2010 | 5 | 0.380 |
Why?
|
| Dietary Supplements | 3 | 2012 | 185 | 0.370 |
Why?
|
| Interleukins | 1 | 2010 | 19 | 0.370 |
Why?
|
| North Carolina | 4 | 2019 | 1514 | 0.370 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2010 | 46 | 0.370 |
Why?
|
| Sarcopenia | 3 | 2017 | 64 | 0.370 |
Why?
|
| Exercise Therapy | 1 | 2013 | 270 | 0.350 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 765 | 0.350 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 125 | 0.350 |
Why?
|
| Enzymes | 1 | 2009 | 5 | 0.340 |
Why?
|
| Fish Oils | 1 | 2009 | 36 | 0.340 |
Why?
|
| Plant Preparations | 1 | 2009 | 27 | 0.340 |
Why?
|
| Soybeans | 1 | 2009 | 35 | 0.340 |
Why?
|
| Lipoprotein(a) | 1 | 2009 | 21 | 0.340 |
Why?
|
| Cell Adhesion Molecules | 1 | 2009 | 43 | 0.330 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2018 | 918 | 0.320 |
Why?
|
| Double-Blind Method | 3 | 2021 | 525 | 0.320 |
Why?
|
| Lipids | 1 | 2010 | 232 | 0.320 |
Why?
|
| Renal Dialysis | 2 | 2009 | 282 | 0.320 |
Why?
|
| Muscular Atrophy | 1 | 2009 | 71 | 0.320 |
Why?
|
| Hyperhomocysteinemia | 1 | 2008 | 5 | 0.310 |
Why?
|
| Homocysteine | 1 | 2008 | 14 | 0.310 |
Why?
|
| Lumbar Vertebrae | 3 | 2019 | 101 | 0.310 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2008 | 29 | 0.310 |
Why?
|
| Docosahexaenoic Acids | 1 | 2008 | 21 | 0.310 |
Why?
|
| Time Factors | 4 | 2017 | 2149 | 0.310 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 3990 | 0.300 |
Why?
|
| Osteoporosis | 3 | 2024 | 70 | 0.290 |
Why?
|
| Energy Intake | 2 | 2019 | 128 | 0.280 |
Why?
|
| Health Status | 3 | 2016 | 399 | 0.270 |
Why?
|
| Prospective Studies | 5 | 2015 | 2282 | 0.270 |
Why?
|
| Treatment Outcome | 6 | 2020 | 3306 | 0.260 |
Why?
|
| Survival Analysis | 2 | 2017 | 483 | 0.230 |
Why?
|
| Research Design | 1 | 2024 | 313 | 0.210 |
Why?
|
| Prevalence | 3 | 2017 | 981 | 0.200 |
Why?
|
| Prognosis | 2 | 2017 | 1497 | 0.190 |
Why?
|
| Carbohydrate Metabolism | 1 | 2020 | 17 | 0.190 |
Why?
|
| Self-Help Devices | 1 | 2020 | 8 | 0.190 |
Why?
|
| Accidents, Home | 1 | 2020 | 17 | 0.180 |
Why?
|
| Environment Design | 1 | 2020 | 18 | 0.180 |
Why?
|
| Femur Neck | 2 | 2017 | 21 | 0.180 |
Why?
|
| Amino Acids | 1 | 2020 | 46 | 0.180 |
Why?
|
| Metabolomics | 1 | 2020 | 54 | 0.180 |
Why?
|
| Glutathione Peroxidase | 2 | 2010 | 9 | 0.180 |
Why?
|
| Housing | 1 | 2020 | 65 | 0.170 |
Why?
|
| Superoxide Dismutase | 2 | 2010 | 45 | 0.170 |
Why?
|
| Cyclooxygenase 2 | 2 | 2010 | 48 | 0.170 |
Why?
|
| Disability Evaluation | 3 | 2020 | 240 | 0.170 |
Why?
|
| United States | 3 | 2016 | 3939 | 0.170 |
Why?
|
| Animals | 5 | 2017 | 7541 | 0.170 |
Why?
|
| Exercise Test | 2 | 2019 | 227 | 0.170 |
Why?
|
| Hip | 1 | 2019 | 15 | 0.160 |
Why?
|
| Femur | 1 | 2019 | 74 | 0.160 |
Why?
|
| Compressive Strength | 1 | 2018 | 23 | 0.160 |
Why?
|
| Clothing | 1 | 2018 | 6 | 0.150 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2017 | 23 | 0.150 |
Why?
|
| Oxygen Consumption | 3 | 2019 | 154 | 0.150 |
Why?
|
| Hand Strength | 2 | 2015 | 101 | 0.140 |
Why?
|
| Muscle Denervation | 1 | 2017 | 29 | 0.140 |
Why?
|
| Muscle Fibers, Fast-Twitch | 1 | 2017 | 30 | 0.140 |
Why?
|
| Hip Fractures | 1 | 2017 | 31 | 0.140 |
Why?
|
| Risk Assessment | 4 | 2017 | 1426 | 0.140 |
Why?
|
| Behavior Therapy | 2 | 2016 | 103 | 0.140 |
Why?
|
| Thigh | 1 | 2016 | 42 | 0.130 |
Why?
|
| Troponin T | 1 | 2017 | 81 | 0.130 |
Why?
|
| Women | 1 | 2015 | 12 | 0.130 |
Why?
|
| Analysis of Variance | 2 | 2014 | 463 | 0.130 |
Why?
|
| Geriatric Assessment | 2 | 2020 | 390 | 0.130 |
Why?
|
| Postoperative Complications | 1 | 2020 | 780 | 0.130 |
Why?
|
| Wrist Injuries | 1 | 2015 | 43 | 0.130 |
Why?
|
| Neuropsychological Tests | 1 | 2016 | 371 | 0.130 |
Why?
|
| Cohort Studies | 2 | 2016 | 1817 | 0.120 |
Why?
|
| Ankle Brachial Index | 1 | 2014 | 39 | 0.120 |
Why?
|
| Retrospective Studies | 3 | 2017 | 3509 | 0.120 |
Why?
|
| Interleukin-1beta | 2 | 2012 | 42 | 0.110 |
Why?
|
| Heart Function Tests | 1 | 2013 | 9 | 0.110 |
Why?
|
| Risk | 1 | 2015 | 321 | 0.110 |
Why?
|
| Recurrence | 1 | 2014 | 263 | 0.110 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2013 | 16 | 0.110 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2013 | 13 | 0.110 |
Why?
|
| Interleukin-8 | 1 | 2013 | 26 | 0.110 |
Why?
|
| Movement Disorders | 1 | 2013 | 26 | 0.110 |
Why?
|
| Muscle Development | 1 | 2013 | 49 | 0.110 |
Why?
|
| Community Health Centers | 1 | 2013 | 16 | 0.110 |
Why?
|
| C-Reactive Protein | 2 | 2012 | 238 | 0.110 |
Why?
|
| Leptin | 1 | 2013 | 71 | 0.110 |
Why?
|
| Body Weights and Measures | 1 | 2013 | 24 | 0.110 |
Why?
|
| Triglycerides | 2 | 2012 | 230 | 0.110 |
Why?
|
| Body Weight | 1 | 2015 | 310 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 560 | 0.110 |
Why?
|
| Dairy Products | 1 | 2012 | 13 | 0.100 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 73 | 0.100 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 767 | 0.100 |
Why?
|
| Disease Progression | 1 | 2014 | 594 | 0.100 |
Why?
|
| Independent Living | 1 | 2013 | 99 | 0.100 |
Why?
|
| Health Education | 1 | 2013 | 157 | 0.100 |
Why?
|
| Body Fluid Compartments | 1 | 2011 | 5 | 0.100 |
Why?
|
| Sex Factors | 1 | 2013 | 663 | 0.100 |
Why?
|
| Food, Formulated | 1 | 2011 | 12 | 0.100 |
Why?
|
| Health Behavior | 1 | 2013 | 232 | 0.090 |
Why?
|
| Mobility Limitation | 1 | 2013 | 219 | 0.090 |
Why?
|
| Fibrinogen | 1 | 2011 | 44 | 0.090 |
Why?
|
| Leukocyte Count | 1 | 2011 | 49 | 0.090 |
Why?
|
| Adult | 4 | 2014 | 9345 | 0.090 |
Why?
|
| Vasodilator Agents | 1 | 2010 | 62 | 0.090 |
Why?
|
| Cattle | 1 | 2010 | 103 | 0.090 |
Why?
|
| Bayes Theorem | 1 | 2010 | 80 | 0.090 |
Why?
|
| Lipoproteins, LDL | 1 | 2010 | 81 | 0.090 |
Why?
|
| Vasodilation | 1 | 2010 | 94 | 0.090 |
Why?
|
| Models, Biological | 1 | 2012 | 392 | 0.090 |
Why?
|
| Endothelium, Vascular | 1 | 2010 | 156 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 210 | 0.080 |
Why?
|
| Health Promotion | 1 | 2011 | 246 | 0.080 |
Why?
|
| Health Surveys | 1 | 2009 | 196 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2010 | 406 | 0.080 |
Why?
|
| Texas | 1 | 2008 | 36 | 0.080 |
Why?
|
| Reactive Oxygen Species | 1 | 2009 | 157 | 0.080 |
Why?
|
| Interviews as Topic | 1 | 2009 | 263 | 0.080 |
Why?
|
| Lipoproteins, HDL | 1 | 2010 | 251 | 0.080 |
Why?
|
| Nutrition Surveys | 1 | 2009 | 148 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2009 | 472 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2008 | 189 | 0.070 |
Why?
|
| Cross-Sectional Studies | 1 | 2009 | 1531 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 582 | 0.060 |
Why?
|
| Program Evaluation | 2 | 2018 | 185 | 0.060 |
Why?
|
| Blood Glucose | 2 | 2019 | 494 | 0.060 |
Why?
|
| Incidence | 2 | 2015 | 1199 | 0.050 |
Why?
|
| Energy Metabolism | 2 | 2014 | 147 | 0.050 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 257 | 0.040 |
Why?
|
| Fatigue | 1 | 2019 | 85 | 0.040 |
Why?
|
| Women's Health | 1 | 2020 | 235 | 0.040 |
Why?
|
| Exercise Tolerance | 1 | 2019 | 125 | 0.040 |
Why?
|
| Finite Element Analysis | 1 | 2018 | 82 | 0.040 |
Why?
|
| Cyclic AMP-Dependent Protein Kinase RIIalpha Subunit | 1 | 2017 | 9 | 0.040 |
Why?
|
| Causality | 1 | 2017 | 38 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2017 | 91 | 0.040 |
Why?
|
| California | 1 | 2017 | 62 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2018 | 293 | 0.040 |
Why?
|
| Neuromuscular Junction | 1 | 2017 | 72 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 2017 | 114 | 0.030 |
Why?
|
| Organ Size | 1 | 2017 | 218 | 0.030 |
Why?
|
| Action Potentials | 1 | 2017 | 178 | 0.030 |
Why?
|
| Synaptic Transmission | 1 | 2017 | 117 | 0.030 |
Why?
|
| Spine | 1 | 2015 | 41 | 0.030 |
Why?
|
| Publication Bias | 1 | 2015 | 8 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 566 | 0.030 |
Why?
|
| Calibration | 1 | 2015 | 28 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 753 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 762 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 206 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 495 | 0.030 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2015 | 199 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 876 | 0.030 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2012 | 3 | 0.030 |
Why?
|
| Accidents, Traffic | 1 | 2015 | 195 | 0.030 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2012 | 9 | 0.030 |
Why?
|
| Ubiquitin | 1 | 2012 | 15 | 0.030 |
Why?
|
| Running | 1 | 2012 | 19 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2012 | 177 | 0.030 |
Why?
|
| Calpain | 1 | 2012 | 13 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2012 | 77 | 0.030 |
Why?
|
| Muscle Proteins | 1 | 2012 | 59 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2012 | 173 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 198 | 0.020 |
Why?
|
| Basal Metabolism | 1 | 2011 | 9 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 2484 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 105 | 0.020 |
Why?
|
| Insulin | 1 | 2012 | 367 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2012 | 508 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 684 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 225 | 0.020 |
Why?
|
| Heart Rate | 1 | 2011 | 335 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 217 | 0.020 |
Why?
|